Appili Therapeutics Inc.
$3,586,813.00
843,956.00 at $0.46
Initial Public Offering - Closed - Tuesday, June 25, 2019
Company Description
Appili Therapeutics Inc. is a pharmaceutical company focused on the acquisition and development of novel treatments targeting unmet needs in infectious disease.
| Address: |
1344 Summer Street, Suite 415 Halifax, Nova Scotia, B3H 0A8 Canada |
|---|---|
| Phone Number: | 902 442 4655 |
| Fax Number: | |
| Website: |
| Industry: | Pharmaceuticals |
|---|---|
| Closing Date: | Tuesday, June 25, 2019 |
| 1st Day of Trading: | Tuesday, June 25, 2019 |
| Primary Symbol: | APLI |
| Exchange: | Venture |
Proceeds
The net proceeds of the offering will be used to pay for manufacturing and partnering activities associated with identification of commercial partners, the chemistry and biological with goal of lead candidate development, for the support activities to complement Defense Threat Reduction Agency, for the funding activities including manufacturing, regulatory and preclinical costs, other research and development activities supporting the above programs including rent, project management and scientific advisors and other key opinion leaders, business development – costs incurred relating to assessing and evaluating new drug product candidates that fit within the Company’s strategic focus, as well as out-licensing of existing programs and unallocated general and administrative expenses.
| Gross Proceeds: | $3,586,813.00 |
|---|---|
| Underwrting Fees: | $147,043.00 |
| Expense Offering: | $847,245.00 |
| Net Proceeds: | $2,592,525.00 |
| Lead Underwriter: | Mackie Research Capital Corporation |
|---|---|
| Other Underwriter(s): |
Bloom Burton & Co. Ltd Echelon Wealth Partners Inc. |
Performance
| 1 day | 1 week | 1 month | 6 months | Inception | |
|---|---|---|---|---|---|
| Recent Performance | 0.00 % | 0.00 % | 33.33 % | 0.00 % | -91.25 % |
| Post IPO Performance | 75.05 % | 75.05 % | 64.11 % |
The content of this page is transmitted strictly for informational purposes. Investments must be selected in accordance with the investor's respective objectives. Desjardins Online Brokerage does not issue any recommendations or endorsements concerning any particular product, its potential value or appropriateness, or any specific strategy. It is highly recommended to read the prospectus before making any type of investment.